What is the share price of Eli Lilly (LLY)?

Eli Lilly last traded at $1,179.11 (+0.9% on the day), as of 7/17/2026. For education only, not investment advice.

What is Eli Lilly's revenue?

Eli Lilly reported revenue of $65.2B for FY2025, with net profit of $20.6B.

What is the P/E ratio of LLY?

Eli Lilly trades at a trailing P/E of about 49.5.

Eli Lilly

LLY · NYSE · Pharma · United States

$1,179.11+0.9%

Delayed · as reported by Yahoo Finance · as of Jul 17, 2026, 8:03 PM

Snapshot

TickerLLY

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees50,000

HeadquartersIndianapolis, United States

Market cap$1051.5B

P/E (TTM)49.5

P/B33.8

Volume2.16M

Websitewww.lilly.com

Filings tracked4

About Eli Lilly — read

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions85.3%
Public & other14.6%

5,601 institutional holders

As reported by Yahoo Finance.

Forensic check

Cash conversion · 3y0.82×

Cumulative operating cash flow ÷ cumulative net profit over 3 reported years ($29.9B vs $36.5B).

Above 1.0× means reported profit was more than covered by cash the business actually generated. Below 1.0× over several years means profit isn’t converting to cash — commonly explained by working capital funding growth, and worth reading alongside the cash-flow statement.

Computed by MarketChacha from reported annual figures (SEC XBRL). Not a rating or recommendation.

$623.7852-wk range$1,249.45

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Market cap

$1051.5B

Day change

+0.9%

P/E (TTM)

49.5

Fwd P/E

26.3

P/B

33.8

Div yield

0.59%

Beta

0.51

Revenue (FY2025)

$65.2B

Net margin

31.7%

ROE

77.8%

Revenue CAGR (2y)

+38.2%

Profit CAGR (2y)

+98.5%

EPS (FY2025)

22.95

Net profit (FY2025)

$20.6B

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about LLY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jun 26, 2026+7.1%
Eli Lilly shares rose sharply after the European Medicines Agency's CHMP issued a positive opinion recommending expanded approval of its oncology drug Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia across all lines of therapy.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about LLY

Why is Eli Lilly (LLY) up ~6% to a record high today?c/usmarkets · 6/26/2026▲ 1

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$65.2B	$20.6B	22.95	31.7%	77.8%
FY2024	$45.0B	$10.6B	11.71	23.5%	74.2%
FY2023	$34.1B	$5.2B	5.80	15.4%	48.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$19.8B	$7.4B	8.26	37.4%
2025Q3	$17.6B	$5.6B	6.21	31.7%
2025Q2	$15.6B	$5.7B	6.29	36.4%
2025Q1	$12.7B	$2.8B	3.06	21.7%
2024Q3	$11.4B	$970.3M	1.07	8.5%
2024Q2	$11.3B	$3.0B	3.28	26.3%
2024Q1	$8.8B	$2.2B	2.48	25.6%
2023Q3	$9.5B	$-57.4M	-0.06	-0.6%
2023Q2	$8.3B	$1.8B	1.95	21.2%
2023Q1	$7.0B	$1.3B	1.49	19.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events, Exhibits
SEC5/20/2026material
8-K — Shareholder vote results
SEC5/7/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.